VTV Therapeutics Inc. Class AVTVT
13F holders, Q1 2025 (March 31)21holders +4
5new positions
1sold out
$17.32avg. 13F price*
At the end of Q1 2025, 21 institutions reported holding VTV Therapeutics Inc. Class A (VTVT) in their 13F filings, up 4 from Q4 2024. 5 opened new positions and 1 sold out. The largest holders were Samsara Biocapital, LLC ($3.6M), FMR LLC ($3.1M) and Baker Bros. Advisors LP ($1.7M).
- Company
- VTV Therapeutics Inc. Class A
- CUSIP
- 918385204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $441K |
| Exits | 1 | $268 |
All 13F filers, Q4 2024 → Q1 2025: 26,457 shares bought and 6,154 shares sold, net +20,303 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 21 holders
| Samsara Biocapital, LLC | 0.64% | No change | 206,784 | $3.6M |
| FMR LLC | 0.00% | No change | 178,200 | $3.1M |
| Baker Bros. Advisors LP | 0.02% | No change | 97,314 | $1.7M |
| Vanguard Group Inc. | 0.00% | No change | 41,558 | $720K |
| Northern Trust Corp. | 0.00% | New | 15,626 | $271K |
| Geode Capital Management, LLC | 0.00% | Add +8.6% | 12,637 | $219K |
| Connective Capital Management, LLC | 0.15% | New | 9,377 | $162K |
| BlackRock, Inc. | 0.00% | Reduce -1.4% | 4,704 | $81K |
| UBS Group AG | 0.00% | Reduce -46.2% | 4,040 | $70K |
| Morgan Stanley | 0.00% | Reduce -34.9% | 746 | $13K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 394 | $7K |
| Osaic Holdings, Inc. | 0.00% | Reduce -10.6% | 152 | $3K |
| Activest Wealth Management | 0.00% | No change | 50 | $866 |
| CoreCap Advisors, LLC | 0.00% | New | 45 | $779 |
| Parallel Advisors, LLC | 0.00% | No change | 38 | $658 |
| Sunbelt Securities, Inc. | 0.00% | No change | 15 | $260 |
| Bank of America Corp. | 0.00% | Add +25.0% | 10 | $173 |
| SBI Securities Co., Ltd. | 0.00% | New | 10 | $173 |
| BNP Paribas Financial Markets | 0.00% | No change | 9 | $156 |
| JPMorgan Chase & Co. | 0.00% | Reduce -99.8% | 3 | $52 |
| Royal Bank of Canada | 0.00% | Reduce -98.2% | 7 | $0 |
"% of holder's portfolio" is VTVT's weight in each manager's 13F, not the share of VTV Therapeutics Inc. Class A the manager owns.